Three companies with late-stage development programs for the treatment of AML are expected to provide updates at the 2011 ASCO annual meeting.
To Partner, or Not to Partner: That is the Question
March 10, 2011 By 3 Comments
Traditional wisdom holds that biotechnology companies benefit from collaborations with their larger pharmaceutical peers, which can help validate a company’s technology, provide capital to help fund clinical development, and enable access to experienced clinical, regulatory and commercial infrastructure. While this was certainly true in the early days of biotechnology, the industry has now matured – [...]
Cyclacel Pharmaceuticals, Inc.
January 1, 2011 By Leave a Comment
Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. The Company has three orally-available product candidates in clinical development, for which Cyclacel has retained rights in most global markets. Through Cyclacel’s ALIGN Pharmaceuticals subsidiary, the Company markets Xclair® [...]
Investment Opportunities with Five Frontline Therapies for AML
September 6, 2010 By 2 Comments
Acute myelogenous leukemia [AML] is a fast-growing cancer of the blood and bone marrow. Unformed cells called myeloblasts, or “blasts,” reside in the bone marrow and normally become a particular kind of cell – a white blood cell, red blood cell, or platelet. In AML, abnormal blasts produce white blood cells that do not function [...]
Cyclin-dependent Cancer Confab Preview
April 16, 2010 By Leave a Comment
For more than a century, the American Association of Cancer Research [AACR] has held its annual meeting and this weekend will kick off the 101st event in Washington, DC, which is being held April 17-21, 2010. Many pharmaceutical and biotechnology companies will be presenting new data and approximately 6,300 abstracts will be discussed in oral [...]
Follow MD Becker Partners